March 26th 2024
The hospitalization risk was reduced to up to 75% for patients with heart disease treated with both antidepressants and psychotherapy to manage anxiety or depression symptoms.
Expert Panel Supports Intravascular Ultrasound Use in Peripheral Interventions
January 9th 2024A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.
Discussing Advances in Structural Heart Disease, with Elliot Elias, MD, MPH
September 15th 2023Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.
FDA Approves Updated Label for Mavacamten in Obstructive Hypertrophic Cardiomyopathy
June 16th 2023On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.
Analysis Predicts Obesity as Leading Risk Factor for Heart Attacks by 2050
June 8th 2023An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
Immediate Complete Revascularization Non-Inferior to Staged Procedure in BIOVASC Trial
March 5th 2023In patients with acute coronary syndrome and multi-vessel heart disease, immediate stent treatment was as safe and effective as staged treatment at one year, according to late-breaking data presented at ACC 2023.
Analysis Provides Updated Overview of Risk with Mitral Valve Repair for Mitral Regurgitation
January 20th 2023An analysis of data from the STS Adult Cardiac Surgery Database provides an updated overview of the risks of mortality, morbidity, and conversion-to-replacement among patients undergoing mitral valve repair for primary mitral regurgitation.
TAVI Associated with Lower Risk of Structural Valve Deterioration than Surgery
December 16th 2022An analysis of data from randomized clinical trials and non-randomized trials comparing TAVI and surgery provides an overview of 5-year incidence, outcomes, and predictors of structural valve deterioration with both approaches.
ACC and AHA Release Updated Guidance for Diagnosis and Management of Aortic Disease
November 3rd 2022Released on Nov. 2, the 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease were created to be used concurrently with guidance published in 2020 and to replace previous guidance published in 2010 and 2015.
PASCAL System Demonstrates Noninferiority to MitraClip for DMR in CLASP IID Trial
September 19th 2022Data from the CLASP IID trial provide insight into the benefits of the PASCAL TEER system for degenerative mitral regurgitation, which demonstrated noninferiority to the MitraClip system for the trial's primary safety and efficacy endpoints.
PROTECTED TAVR: Cerebral Embolic Protection Devices Do Not Reduce Stroke Risk
September 17th 2022Results of the PROTECTED TAVR trial suggest use of cerebral embolic protection devices was not associated with a reduction in risk of stroke within the first 72 hours after TAVR or prior to hospital discharge among patients with aortic stenosis.
FDA Approves PASCAL Precision System for TEER in Degenerative Mitral Regurgitation
September 16th 2022Announced on September 15 by Edwards Lifesciences Corporation, the PASCAL Precision transcatheter valve repair system has received approval for transcatheter edge-to-edge repair in patients with degenerative mitral regurgitation.